Jazz Pharmaceuticals plc - Ordinary Shares (JAZZ) Social Stream



Jazz Pharmaceuticals plc - Ordinary Shares (JAZZ): $111.08

1.81 (+1.66%)

POWR Rating

Component Grades

Momentum

C

Stability

C

Sentiment

Quality

B

Add JAZZ to Watchlist
Sign Up

Industry: Biotech

Industry

F

Ranked

#2 of 362

in industry

Featured Post From StockTwits About JAZZ

$JAZZ Here’s why this will fly next week despite a disappointing past two days:

3 BILLION in revenue projected for this year, the market cap is 8 Billion, HOLY CRAP people!!! Yahoo is showing forward P/E of 8, they could blow that out of the water!

1. EPS Q2 beat expectations.
2. FDA approval for Xywav has exclusivity with orphan drug status and it’s a 300M marketable drug minimum, everyone in America struggles with sleeping!
3. 27 drugs in their pipeline listed on website
4. Cancer, Cannabis and Sleep related drugs as flagship pipeline candidates.
5. They are based in Ireland so they have the European and USA market access.
6. Small Cell Lung Cancer drug approved with 55 million in sales and forward guidance climbing.
7. (4) Neuro/Cancer drugs ready to be mass produced, aka they haven’t been priced in yet.
8. Pipeline of drugs to treat

$JNJ $PFE $OCGN
_MatadorTrading, published August 13, 2021

What Else are JAZZ Traders Talking About?


Other tickers frequently mentioned alongside JAZZ are PFE and OCGN.

Loading social stream, please wait...


Get Free Updates

Join thousands of investors who get the latest news, insights and top rated picks from StockNews.com!